Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1996-1-18
|
pubmed:abstractText |
The type I growth factor receptor family is increasingly recognized as important in the development and maintenance of breast cancer. The family currently consists of four closely related members: the epidermal growth factor receptor (EGF-R/erbB-1), erbB-2, erbB-3 and erbB-4. Putative ligands which bind directly to or indirectly activate erbB-2/3/4 have been characterized recently. This still growing family of EGF-related growth factors includes gp30, its homolog heregulin (HRG), the rat homolog neu differentiation factor (NDF), glial growth factors (GLIA), ARIA and a 50 kDa factor from COLO 16 cells. The understanding of the function, biology and interactions of these growth factor receptors and their ligands will have far-reaching implications for the prognosis and treatment of breast cancer. This review focuses on advances and future directions for further investigations intended to clarify the mechanism and significance of erbB/ligand interactions in breast cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1044-579X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
6
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
135-45
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:7495981-Animals,
pubmed-meshheading:7495981-Breast Neoplasms,
pubmed-meshheading:7495981-Disease Progression,
pubmed-meshheading:7495981-Drug Interactions,
pubmed-meshheading:7495981-Drug Resistance, Neoplasm,
pubmed-meshheading:7495981-Humans,
pubmed-meshheading:7495981-Proto-Oncogene Proteins,
pubmed-meshheading:7495981-Rats,
pubmed-meshheading:7495981-Receptor, Epidermal Growth Factor,
pubmed-meshheading:7495981-Receptor, erbB-2,
pubmed-meshheading:7495981-Receptor, erbB-3
|
pubmed:year |
1995
|
pubmed:articleTitle |
Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance.
|
pubmed:affiliation |
Vincent T. Lombardi Cancer Research Center, Georgetown University School of Medicine, Lombardi Cancer Research Center S-122, Washington, DC 20007, USA.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Review
|